Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04565249 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19
A Phase 2 study, sponsored by Pliant Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04565249: Clinical Trial Phase 2 study, sponsored by Pliant Therapeutics.
NCT04565249 is a Phase 2 study that was terminated before completion, run by Pliant Therapeutics. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04565249, a Phase 2 study, was terminated before completion, sponsored by Pliant Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19
Primary Outcome
Number of Participants With Treatment-related Adverse Events and Laboratory Abnormalities which was Assessed by CTCAE V5.
Interventions
- DRUG Placebo
- DRUG PLN-74809
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-10-22 |
| Est. Completion | 2021-08-02 |
| Phase | Phase 2 |
Why NCT04565249 stopped before completion
NCT04565249 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04565249 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04565249 about?
NCT04565249 is a clinical study titled "Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19". Evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19
What is the current status of trial NCT04565249?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2020-10-22. Estimated completion is 2021-08-02.
What interventions are being tested in trial NCT04565249?
The interventions under investigation include: Placebo (DRUG), PLN-74809 (DRUG).
Who is sponsoring clinical trial NCT04565249?
This trial is sponsored by Pliant Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04565249's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI